These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24942356)

  • 1. Drug-induced gastrointestinal disorders.
    Philpott HL; Nandurkar S; Lubel J; Gibson PR
    Postgrad Med J; 2014 Jul; 90(1065):411-9. PubMed ID: 24942356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced gastrointestinal disorders.
    Philpott HL; Nandurkar S; Lubel J; Gibson PR
    Frontline Gastroenterol; 2014 Jan; 5(1):49-57. PubMed ID: 28839751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal and liver adverse effects of drugs used for treating IBD.
    Rogler G
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):157-65. PubMed ID: 20227029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PSYCHOSOMATIC RELATIONSHIPS DURING GASTROINTESTINAL DISEASE ON THE MODEL OF IRRITABLE BOWEL SYNDROME].
    Elfimova EV; Elfimov MA; Berezkin AS
    Eksp Klin Gastroenterol; 2015; (4):83-8. PubMed ID: 26415271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal events related to the use of non-steroidal anti-inflammatory drugs: some clinical and economic aspects.
    Eliakim R; Rachmilewitz D
    Isr J Med Sci; 1997 Oct; 33(10):696-9. PubMed ID: 9397147
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach.
    Azevedo LF; Magro F; Portela F; Lago P; Deus J; Cotter J; Cremers I; Vieira A; Peixe P; Caldeira P; Lopes H; Gonçalves R; Reis J; Cravo M; Barros L; Ministro P; Lurdes M; Duarte A; Campos M; Carvalho L; Costa-Pereira A
    Pharmacoepidemiol Drug Saf; 2010 May; 19(5):499-510. PubMed ID: 20306455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease.
    Whelan K; Quigley EM
    Curr Opin Gastroenterol; 2013 Mar; 29(2):184-9. PubMed ID: 23286925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
    Cryer B; Miller P; Petruschke RA; Chen E; Geba GP; Papp AE
    Aliment Pharmacol Ther; 2005 Mar; 21(5):599-607. PubMed ID: 15740544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs.
    Pilotto A; Franceschi M; Vitale DF; Zaninelli A; Masotti G; Rengo F; ;
    Aliment Pharmacol Ther; 2005 Jul; 22(2):147-55. PubMed ID: 16011673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options in irritable bowel syndrome.
    Farthing MJ
    Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):773-86. PubMed ID: 15324713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How safe are the safest IBD drugs?
    Lewis JD
    Gastroenterology; 2003 Jun; 124(7):1986-7; discussion 1987-8. PubMed ID: 12806636
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
    Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
    J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "I know this is bad for me, but...": a qualitative investigation of women with irritable bowel syndrome and inflammatory bowel disease: part II.
    Fletcher PC; Jamieson AE; Schneider MA; Harry RJ
    Clin Nurse Spec; 2008; 22(4):184-91. PubMed ID: 18596487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enteropathy induced by nonsteroid anti-inflammatory drugs].
    Karateev AE; Nasonova VA
    Ter Arkh; 2004; 76(2):79-82. PubMed ID: 15106423
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of NSAID complications: gastrointestinal and more.
    Beehrle DM; Evans D
    Lippincotts Prim Care Pract; 1999; 3(3):305-15. PubMed ID: 10711132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication-induced hyperprolactinemia.
    Molitch ME
    Mayo Clin Proc; 2005 Aug; 80(8):1050-7. PubMed ID: 16092584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.
    Katzka DA; Loftus EV; Camilleri M
    Clin Pharmacol Ther; 2012 Sep; 92(3):306-20. PubMed ID: 22828717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.